BioMedNewsBreaks

TuesdayJun 02, 2026 10:00 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. Durkacz said the therapy is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments. Durkacz also discussed Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood…

Continue Reading

TuesdayJun 02, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

HeartBeam (NASDAQ: BEAT) a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. HeartBeam said the proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said…

Continue Reading

MondayJun 01, 2026 2:15 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company's approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities. The company is also pursuing a platform-based model through Deciparticle and its AI-enhanced PDAOAI biomedical infrastructure initiative, positioning itself at the intersection of oncology, nanomedicine and artificial intelligence. Growing…

Continue Reading

MondayJun 01, 2026 10:00 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Shifts Focus to AI Energy Infrastructure, Adds Denham Capital Founder to Board

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the growing power demands of artificial intelligence and hyperscale data centers. As part of the transition, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company's board of directors. LIXTE said its strategy will target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies, while it seeks a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.…

Continue Reading

FridayMay 29, 2026 12:27 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Advances Simplified Cartilage Repair Platform Toward Key Commercial Milestones

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC®, a cell-free hydrogel implant designed to simplify knee cartilage repair through a single-step, approximately 10-minute procedure that may offer an alternative to traditional microfracture and complex cell-based therapies. The company is targeting an estimated $3 billion U.S. market encompassing roughly 470,000 annual knee cartilage repair cases, where no approved off-the-shelf regenerative solution currently exists. Clinical data have shown approximately 100% greater pain improvement versus microfracture, alongside MRI-confirmed regeneration of near-native cartilage and durable multi-year outcomes. GelrinC® has already secured CE Mark approval in Europe and is currently progressing through a pivotal…

Continue Reading

FridayMay 29, 2026 11:15 am

BioMedNewsBreaks — Redwood AI Corp. (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ) Signs LOI to Acquire Quantum Cybersecurity Company Quantum.IQ

This article has been disseminated on behalf of Redwood AI Corp. and may include paid advertising.  Redwood AI (CSE: AIRX) (OTCQB: RDWCF) (Frankfurt: Y0N) (WKN: A422EZ)  announced it has entered into a non-binding letter of intent to explore the acquisition of Vancouver-based Quantum.IQ, an AI-driven quantum cybersecurity company focused on helping organizations prepare for emerging quantum-enabled cyber threats. Quantum.IQ's post-quantum cryptography platform is designed to assist government, defense, financial services and critical infrastructure organizations in assessing cryptographic vulnerabilities, planning migration to quantum-resistant security systems and monitoring ongoing cybersecurity readiness. Under the proposed transaction, Redwood would acquire all outstanding shares of Quantum.IQ in exchange for up to 14 million Redwood common shares, including milestone-based consideration, with all shares subject to a staged escrow release…

Continue Reading

ThursdayMay 28, 2026 12:43 pm

BioMedNewsBreaks — Regentis Biomaterials Ltd. (NYSE American: RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant

Regentis Biomaterials Ltd. (NYSE American: RGNT) is advancing GelrinC(R), a cell-free hydrogel implant designed to repair knee cartilage damage through a single approximately 10-minute procedure, positioning the company to address a major unmet need in orthopedic medicine. While roughly 472,500 arthroscopic knee procedures in the U.S. each year involve cartilage damage, no approved off-the-shelf regenerative solution capable of restoring hyaline-like cartilage currently exists in the U.S. market. Unlike traditional microfracture procedures or complex cell-based therapies that often require multiple surgeries and lengthy preparation, GelrinC(R) is designed as a ready-to-use implant that supports native cartilage regeneration over time. The product has…

Continue Reading

ThursdayMay 28, 2026 12:35 pm

BioMedNewsBreaks — Jupiter Neurosciences Inc. (NASDAQ: JUNS) Closes $2 Million Registered Direct Offering 

Jupiter Neurosciences (NASDAQ: JUNS), a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation, closed its securities purchase agreement for the sale of 7,142,858 shares of common stock in a registered direct offering with gross proceeds of approximately $2.0 million. D. Boral Capital LLC acted as the exclusive placement agent for the offering, which was conducted pursuant to the company’s effective shelf registration statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on April 24, 2026. To view the full press release, visit https://ibn.fm/uymqO About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. (NASDAQ: JUNS) is a clinical-stage biopharmaceutical company…

Continue Reading

ThursdayMay 28, 2026 10:35 am

BioMedNewsBreaks — VERAXA Biotech AG Secures $27.5 Million Senior Secured Financing and $50 Million Equity Line Ahead of Planned Nasdaq Listing 

VERAXA Biotech, a portfolio company of Xlife Sciences AG (SIX: XLS), secured $27.5 million in senior secured convertible note financing from High Trail Capital LP and entered into a share purchase agreement providing access to up to $50 million in equity financing with Lincoln Park Capital Fund LLC. The financing arrangements are intended to strengthen VERAXA’s financial position ahead of its planned business combination with Voyager Acquisition Corp. and anticipated listing on the Nasdaq Capital Market. The High Trail Capital financing includes a 15-month senior secured convertible note and warrants exercisable over four years at an initial exercise price of $11.50 per share, while the…

Continue Reading

ThursdayMay 28, 2026 10:11 am

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Nano to Present Deciparticle(TM) Nanomedicine Platform at BIO International Convention 2026 

Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano announced that Chief Executive Officer Vuong Trieu will present the Deciparticle(TM) nanomedicine platform at the BIO International Convention 2026 in San Diego, highlighting the development of ultra-small nanomedicine formulations designed to enable intravenous administration of highly water-insoluble therapeutics. The Deciparticle(TM) platform utilizes proprietary amphiphilic polymer systems capable of forming sub-20 nanometer particles for oncology and other therapeutic applications. The companies plan to showcase development progress across multiple Deciparticle(TM) programs, including Sapu006, a polysorbate-free intravenous docetaxel formulation moving into Phase 1b clinical evaluation, and Sapu003, an intravenous everolimus nanomedicine program currently in a global Phase 1b clinical trial. The presentation will also highlight the integration…

Continue Reading